Ole Kristian Hjelstuen

Aleap, a non-profit incubator, offers a community for health startups. Our mission is to facilitate innovation and value creation by developing an ecosystem for health startups that allow ambitious entrepreneurs and companies to create new products better and faster. We do this by offering a broad range of critical know-how expertise, flexible infrastructure and international business networks. We believe that entrepreneurship and successful startups will benefit from collaboration in a multidisciplinary environment where sharing with others is fundamental.

Oslo Cancer Cluster Incubator accelerates the development of cancer diagnostics and therapies by facilitating a comprehensive cancer innovation ecosystem. The Incubator is an integrated part of Oslo Cancer Cluster Innovation Park and located next to the Institute of Cancer Research, Oslo University Hospital (Radiumhospitalet) and Ullern Upper Secondary School. The Incubator provides a dynamic, creative and professional growth environment for scientists and start ups, as well as an inspirational campus for students with ambitions in the life sciences. A dedicated team offers members of the Incubator research facilities, business development services and access to an extensive international network of key investors and industrial players. The Incubator holds 5 000 square metres of offices and laboratories including start ups, global pharma, consultants, service providers, investors and research institutions. A wide range of meeting room and auditorium facilities are available on request. The Incubator is supported by the Norwegian government to establish health care business in Norway. The Incubator was opened at Montebello in 2015 and is owned by Oslo Cancer Cluster, Siva, Inven2 and Radforsk.

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 650 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Nansen Neuroscience Network is a knowledge network focusing on innovation in neurosciences by bringing industry and academia together. Neuroscience is on the threshold of discovering the underlying mechanisms for complex mental and cognitive functions, considered by many to be the most challenging and exciting questions in science. It is also one of the fastest developing areas of medical research, and one in which Norway excels and is making significant contributions. Nansen Neuroscience Network aims to be the driving force in connecting brain science and industry, creating smart solutions for individuals and society and improving quality of life through innovation, research and development of diagnostics, therapeutics and preventive measures.

Aleap, a non-profit incubator, offers a community for health startups. Our mission is to facilitate innovation and value creation by developing an ecosystem for health startups that allow ambitious entrepreneurs and companies to create new products better and faster. We do this by offering a broad range of critical know-how expertise, flexible infrastructure and international business networks. We believe that entrepreneurship and successful startups will benefit from collaboration in a multidisciplinary environment where sharing with others is fundamental.

Oslo Cancer Cluster Incubator accelerates the development of cancer diagnostics and therapies by facilitating a comprehensive cancer innovation ecosystem. The Incubator is an integrated part of Oslo Cancer Cluster Innovation Park and located next to the Institute of Cancer Research, Oslo University Hospital (Radiumhospitalet) and Ullern Upper Secondary School. The Incubator provides a dynamic, creative and professional growth environment for scientists and start ups, as well as an inspirational campus for students with ambitions in the life sciences. A dedicated team offers members of the Incubator research facilities, business development services and access to an extensive international network of key investors and industrial players. The Incubator holds 5 000 square metres of offices and laboratories including start ups, global pharma, consultants, service providers, investors and research institutions. A wide range of meeting room and auditorium facilities are available on request. The Incubator is supported by the Norwegian government to establish health care business in Norway. The Incubator was opened at Montebello in 2015 and is owned by Oslo Cancer Cluster, Siva, Inven2 and Radforsk.

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 650 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Nansen Neuroscience Network is a knowledge network focusing on innovation in neurosciences by bringing industry and academia together. Neuroscience is on the threshold of discovering the underlying mechanisms for complex mental and cognitive functions, considered by many to be the most challenging and exciting questions in science. It is also one of the fastest developing areas of medical research, and one in which Norway excels and is making significant contributions. Nansen Neuroscience Network aims to be the driving force in connecting brain science and industry, creating smart solutions for individuals and society and improving quality of life through innovation, research and development of diagnostics, therapeutics and preventive measures.